Objectives: Cardiac syndrome X (CSX) is a clinical entity that is defined as normal coronary arteries with angina pectoris and objective sins of ischemia. The correlation between CSX and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) is well established, however an association with pentraxin-3 (PTX-3) has not been examined. The aim of this study was to investigate the association between PTX-3 and CSX.
C ardiac syndrome X (CSX) is defined as typical chest pain, objective signs of ischemia, and normal coronary arteries in coronary angiogram. [1] CSX is an important clinical entity which constitutes about 10-20% patients who undergo coronary angiography. [2] The exact pathophysiological mechanism of CSX remains obscure, however coronary microcircular abnormalities and endothelial dysfunction have been proposed as potential mechanisms in the etiology of the disease. [3] [4] [5] The association between endothelial dysfunction and inflammation has been well established, and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), intercellular cell adhesion molecule-1, and vascular cell adhesion molecule-1 contribute to the pathophysiology of CSX. [6] Moreover, serum hs-CRP is correlated with symptoms and electrocardiographic markers of myocardial ischemia in patients with CSX. [7] Pentraxin-3 (PTX-3), a newly identified acute phase reactant which resembles CRP structurally and functionally, [8] is produced by many different kinds of cells including macrophages, dendritic cells, neutrophils, fibroblasts, and vascular endothelial cells. [9] Serum PTX-3 levels are elevated in patients with vasculitis, [10] acute myocardial infarction, [11, 12] systemic inflammation or sepsis, [13] psoriasis, unstable angina pectoris, and heart failure. [14] [15] [16] [17] [18] The association between CSX and inflammation and inflammatory markers such as hsCRP is well known, however the pathophysiological role of PTX-3 has not been well established in patients with CSX. [19] Therefore, the aim of the present study is to assess the association between PTX-3 and CSX.
PATIENTS AND METHODS
A total of 122 patients were recruited for this study during a six months period. Eighty two stable angina pectoris (SAP) patients with evidence of ischemia (50 patients with positive treadmill test, 32 patients with positive myocardial perfusion scintography) underwent coronary angiography for suspected coronary artery disease (CAD), and 40 age-and sex-matched outpatient subjects with anginal symptoms and a negative treadmill or myocardial perfusion scan test were included as the control group. Patients with typical chest pain, objective ischemia evidence, and normal coronary angiograms were assigned to the CSX group. Forty one patients were assigned to the CSX group and 41 age-and sex-matched SAP patients with coronary lesions were evaluated as CAD group. Coronary artery stenosis was considered significant in the presence of a luminal diameter narrowing of >50% in any of major coronary arteries or their primary branches. The number of significantly stenosed coronary arteries was recorded (one, two, or three vessels respectively). In order to exclude coronary artery spasm, the patients were asked to breathe rapidly and deeply for five minutes during the coronary angiography procedure. Subjects were excluded if coronary spasm, defined as focal or diffuse narrowing in the coronary arteries, was induced during the hyperventilation test. Patients with acute coronary syndrome, history of previous myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention, secondary hypertension (HT), renal failure, hepatic failure, chronic obstructive lung disease and/or manifest heart disease, such as cardiac failure (left ventricular ejection fraction <50%), atrial fibrillation, and moderate to severe cardiac valve disease were excluded from the study. Similarly, patients with infection, acute stress, chronic systemic inflammatory disease, and those who had been receiving medications affecting the number of leukocytes were also excluded. All the participants included in the study were informed about the study, and oral and written consent to participate voluntarily was obtained.
Fasting blood samples were collected on the day of coronary angiography for the evaluation of serum parameters. Serum PTX-3 level was measured by enzyme immunoassay (EIA) using a quantitative kit (Human PTX-3/TSG-14 Immunoassay, DPTX30, R&D Systems, Inc, MN, USA). For PTX-3, intraassay and inter-assay coefficients of variation (CV) ranged from 3.8% to 4.4% and 4.1% to 6.1%, respectively (minimum detectable concentration: 0.025 ng/ ml). Hs-CRP was measured in the serum by EIA (Immage hs-CRP EIA kit, Beckman Coulter Inc., USA).
Transthoracic echocardiography was performed and the biplane Simpson's ejection fraction (%) was calculated before coronary angiography. HT was defined as having at least two blood pressure measure- 
RESULTS

Baseline characteristics
In total, 122 patients (49.6±6.3 years, 53% male) were included in the study. Patients were categorized Figure 2 ).
DISCUSSION
In this study, we investigated the association between the serum PTX-3 and CSX. In patients with CSX, the levels PTX-3, a newly identified inflammatory marker, were increased relative to the control group and similar to the CAD group. PTX-3 levels were correlated with hs-CRP levels in patients with CSX, consistent with the established association between CSX and other serum markers of inflammation.
Pentraxin-3, produced by various cell types including macrophages, dendritic cells, neutrophils, fibroblasts, and vascular endothelial cells, [9] is essentially an acute phase reactant that is functionally and structurally similar to CRP. [8] PTX-3 is secreted after an inflammatory stimulus and may reflect the local inflammatory status in tissues. [20, 21] Serum PTX-3 levels are elevated in many conditions including acute myocardial infarction, [11, 12] unstable angina pectoris and heart failure, [14] [15] [16] [17] systemic inflammation or sepsis, [13] psoriasis [13] and vasculitis. [10] Higher PTX3 levels into three groups as the control group (n=40), CSX group (n=41), and CAD group (n=41). Baseline clinical, angiographic and laboratory characteristics of the patients groups are shown in Table 1 . Age, sex, HT, diabetes, BMI and medication use were not different between the groups.
The serum levels of hs-CRP and PTX-3 are shown in Figure 1 for each group. Significantly increased PTX-3 levels were observed in the CSX group relative to the control group (0.46±0.16 vs. 0.23±0.09 ng/mL, p<0.001). However there were no difference in the levels of PTX-3 between the CSX and were reported to be associated with adverse cardiovascular outcomes in acute coronary syndromes [12, 22] and stable coronary disease, independent of systemic inflammation. [19] However, to our knowledge, this is the first report demonstrating the association of PTX-3 levels with CSX.
Endothelial dysfunction and impaired coronary microcirculation are two main entities that have been proposed to be responsible for CSX. [3] [4] [5] Indeed, impaired coronary microcirculation is closely related to endothelial dysfunction. The association of inflammatory markers with endothelial dysfunction has been well established. Vane et al. [5] have shown that inflammatory cytokines and growth factors may produce an inflammatory and proliferative response in the vessel wall that may in turn cause microvascular impairment. In other studies, hs-CRP was correlated with angina and profound impairment of endothelial vascular reactivity as well as biomarkers of endothelial dysfunction. [5, 23, 24] In the present study, we found that hs-CRP and PTX-3 were increased in both the CSX and CAD groups relative to the control group. These findings were consistent with the literature regarding the role of inflammation in CSX. We propose that although coronary angiograms revealed normal epicardial coronary arteries in the CSX group, both CSX and CAD groups have similarly increased inflammatory status. It was previously reported that the leukocytes found in the coronary artery lumen are primarily neutrophils. [25] PTX-3 is stored in specific granules of neutrophils and released in response to inflammatory signals. [26] Therefore serum PTX-3 levels may be a more sensitive marker of the inflammatory state in the coronary artery compared to serum hs-CRP. However, the exact role of PTX-3 in the pathophysiology of atherosclerosis is not fully understood. In previous studies, PTX-3 was found to be produced in areas of atherosclerosis, and the production of PTX-3 may contribute to pathogenesis of this disease. [25] It has been suggested that PTX-3 may be part of a protective mechanism, inducing vascular repair by inhibiting fibroblast growth factor-2 or other growth factors responsible for smooth muscle proliferation. [27, 28] However, the pathophysiological role of PTX-3 still remains controversial.
Limitations
The major limitation of the present study is the low number of patients included. Data regarding additional inflammatory markers such as IL-6 and TNF-α, would give a more detailed picture of the inflammatory state in these patients. The CAD group included in our study had stable angina. This group was relatively low risk group when compared to a high-risk disease state such as unstable angina. Therefore, our CAD group reflected only the inflammatory state of stable coronary disease, which may be considered a limitation. Because there was no long-term follow up of these patients, our study provides no prognostic data in terms of future cardiovascular events. In order to rule out coronary artery spasm, a hyperventilation test was performed. Although hyperventilation is a safe provocative test, it is less sensitive in detecting coronary spasm when compared with ergonovine injection, a potential limitation of our study design limitation.
Pentraxin-3, a novel inflammatory marker, is elevated in patients with CSX, similar to the well known inflammatory marker hs-CRP, and may be a promising biomarker in reflecting the inflammatory state of patients with CSX.
